GSK plc Sponsored ADR (GS70)
Summary
GS70 Chart
GSK: Maintaining Strong Buy For LAI HIV Sales Growth And Further Oncology Expansion
GSK plc demonstrates strong oncology pipeline momentum, highlighted by Mo-Rez's phase 1 success in platinum-resistant ovarian and endometrial cancers. Mo-Rez's impressive response rates support five global pivotal phase 3 trials planned for 2026, underscoring GSK's late-stage oncology expansion. GSK's ViiV Healthcare reports Cabenuva's superior viral suppression in HIV, and the company advances key acquisitions and registrational data in multiple myeloma and lung cancer.
GSK to cut up to 1,217 jobs in Belgium, L'Echo says
GSK to cut up to 1,217 jobs in Belgium, L'Echo says
GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength
GSK PLC (LSE:GSK, NYSE:GSK) is expected to deliver a broadly in-line third quarter as weaker vaccine sales are offset by strength in HIV treatments and respiratory drug Nucala, according to RBC Capital Markets. The broker reiterated its Sector Perform rating and 1,975p price target ahead of GSK's results on 28 October, compared with a share price of 1,771p when the note was published.
GSK plc Sponsored ADR (GS70) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has GSK plc Sponsored ADR ever had a stock split?
GSK plc Sponsored ADR Profile
| Pharmaceuticals Industry | Healthcare Sector | Luke Victor Miels CEO | XDUS Exchange | US37733W2044 ISIN |
| GB Country | 66,841 Employees | 14 Aug 2026 Last Dividend | 22 Jul 2022 Last Split | - IPO Date |
Overview
GSK plc, previously known as GlaxoSmithKline plc until its name change in May 2022, stands as a formidable entity in the pharmaceutical sector with a rich history dating back to 1715. With its global headquarters in Brentford, the United Kingdom, GSK focuses on the research, development, and manufacturing of pharmaceuticals, including vaccines and specialty medicines aimed at preventing and treating a myriad of diseases. This multinational corporation has a broad operational footprint spanning the United Kingdom, the United States, and other international markets. GSK is structured into two main operational segments: Commercial Operations and Total R&D (Research & Development), indicating a robust commitment to innovation in healthcare. Additionally, GSK plc actively engages in strategic collaborations, such as those with CureVac for mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for the advancement of oligonucleotide platform technologies.
Products and Services
GSK's portfolio encompasses a wide range of vaccines and medications designed to combat various diseases, underpinned by the company's significant investments in research and development:
- Vaccines: GSK’s vaccine division offers preventive solutions for shingles, meningitis, respiratory syncytial virus (RSV), flu, polio, and influenza. The company also addresses global healthcare needs by developing vaccines for pandemics, illustrating its commitment to public health and safety.
- HIV Medicines: GSK plc is a key player in the fight against HIV/AIDS, providing innovative medicines that are essential in the management of this chronic condition, thereby improving the quality of life for those affected.
- Oncology: The company’s oncology portfolio consists of treatments for various cancers, underscoring GSK's role in advancing cancer care through research and development of new, potentially life-saving therapies.
- Respiratory/Immunology: GSK offers inhaled medications for asthma and chronic obstructive pulmonary disease (COPD), in addition to medicines for other respiratory and immunological conditions. These products reflect the company’s dedication to enhancing respiratory health and immune system management.
- Antibiotics: Recognizing the importance of combating infectious diseases, GSK also manufactures antibiotics to treat a range of infections, contributing to the global fight against antibiotic resistance and infectious threats.
- Collaborative Agreements: Beyond its in-house product line, GSK engages in strategic collaborations to develop next-generation vaccines and therapies, such as mRNA-based influenza vaccines in partnership with CureVac, and advancements in oligonucleotide platform technologies with Wave Life Sciences and Elsie Biotechnologies, Inc. These partnerships are vital to GSK’s strategy of leveraging external expertise and technology to enhance its R&D pipeline.
Contact Information
